Stocklytics Platform
Asset logo for symbol MLTX
MoonLake Immunotherapeutics
MLTX53
$54.43arrow_drop_up0.81%$0.43
Asset logo for symbol MLTX
MLTX53

$54.43

arrow_drop_up0.81%
Key Stats
Open$54.86
Prev. Close$54.24
EPS-1.27
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range54.24
55.32
52 Week Range35.11
64.98
Ratios
Revenue-
EBITDA Margin %-
EPS-1.27
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.68%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

MLTX-
US Healthcare Sector-
US Market-
warning

MLTX / Market

MLTX lose to the US Market which returned 273.33% over the last twenty four hours.
warning

MLTX / Healthcare Sector

MLTX lose to the US Healthcare sector which returned 2.64% over the last twenty four hours.

MoonLake Immunotherapeutics (MLTX) Statistics

MoonLake Immunotherapeutics (MLTX) is a biotechnology company that specializes in the development of immunotherapies for the treatment of various diseases. The company's stock statistics provide valuable insights into its performance in the market. These statistics include information such as the stock price, trading volume, and market capitalization of MLTX. By analyzing these statistics, investors can assess the overall health of the company's stock and make informed investment decisions.
In terms of MLTX's valuation metrics, the company is currently valued at a certain amount per share. This valuation takes into account various factors, including the company's financial performance, growth potential, and market conditions. By evaluating these metrics, investors can gauge whether MLTX is overvalued or undervalued and adjust their investment strategy accordingly.
add MoonLake Immunotherapeutics to watchlist

Keep an eye on MoonLake Immunotherapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has MoonLake Immunotherapeutics (MLTX) stock's performance compared to its sector and the market over the past year?

Over the past year, MoonLake Immunotherapeutics (MLTX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 34.19%, MoonLake Immunotherapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 66.35%, it has fallen short of the market average. This comparison highlights MoonLake Immunotherapeutics's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of MoonLake Immunotherapeutics (MLTX) stock?

The PE ratio for MoonLake Immunotherapeutics (MLTX) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of MoonLake Immunotherapeutics (MLTX) stock?

The Earnings Per Share (EPS) for MoonLake Immunotherapeutics (MLTX), calculated on a diluted basis, is -$1.27. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of MoonLake Immunotherapeutics (MLTX) stock?

The operating margin for MoonLake Immunotherapeutics (MLTX) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of MoonLake Immunotherapeutics (MLTX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of MoonLake Immunotherapeutics (MLTX) is -$108.45M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does MoonLake Immunotherapeutics (MLTX) have?

MoonLake Immunotherapeutics (MLTX) has a total debt of $3.38M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$371.97M.

Take Your Investments to a Whole New Level